Keywords
Last Name
Institution

RAJYALAKSHMI LUTHRA

TitleProfessor
InstitutionMD Anderson
DepartmentHematopathology
Address6565 MD Anderson Blvd
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer. 2017 Aug; 125(8):615-626. PMID: 28475299.
      View in: PubMed
    2. Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. J Neuropathol Exp Neurol. 2017 Mar 01; 76(3):179-188. PMID: 28395087.
      View in: PubMed
    3. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 Jan; 27(1):81-87. PMID: 27785980.
      View in: PubMed
    4. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 Jun; 15(6):1397-404. PMID: 27207774.
      View in: PubMed
    5. Okoye EI, Bruegl AS, Fellman B, Luthra R, Broaddus RR. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers. Int J Gynecol Pathol. 2016 Jan; 35(1):8-15. PMID: 25851713.
      View in: PubMed
    6. Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KP. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol. 2015 Nov; 144(5):746-55. PMID: 26486739.
      View in: PubMed
    7. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21. PMID: 26486734.
      View in: PubMed
    8. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers (Basel). 2015; 7(4):2023-36. PMID: 26473927.
      View in: PubMed
    9. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075.
      View in: PubMed
    10. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159.
      View in: PubMed
    11. Chen H, Luthra R, Goswami RS, Singh RR, Roy-Chowdhuri S. Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel). 2015; 7(3):1699-715. PMID: 26343728.
      View in: PubMed
    12. Gu J, Patel KP, Bai B, Liu CH, Tang G, Kantarjian HM, Tang Z, Abraham R, Luthra R, Medeiros LJ, Lin P, Lu X. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet. 2015; 8:68. PMID: 26300976.
      View in: PubMed
    13. Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, Broaddus RR, Barkoh BA, Manekia J, Yao H, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68. PMID: 26230354.
      View in: PubMed
    14. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 6; 126(6):790-7. PMID: 26124496.
      View in: PubMed
    15. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35. PMID: 26111976.
      View in: PubMed
    16. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3. PMID: 25999449.
      View in: PubMed
    17. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577.
      View in: PubMed
    18. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015; 8:45. PMID: 25952993.
      View in: PubMed
    19. Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, Priyanka P, Muzzafar T, Medeiros LJ, Luthra R, Wang SA. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016 Jan; 96(1):65-71. PMID: 25809997.
      View in: PubMed
    20. Mehrotra M, Patel KP, Chen T, Miranda RN, Wang Y, Zuo Z, Muddasani R, Mishra BM, Abraham R, Luthra R, Lu G. Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):496-505.e1-2. PMID: 26027540.
      View in: PubMed
    21. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, Medeiros LJ, Routbort MJ. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol. 2015 Apr; 39(4):454-61. PMID: 25634750.
      View in: PubMed
    22. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17. PMID: 25754356.
      View in: PubMed
    23. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 1; 21(11):2644-51. PMID: 25695693.
      View in: PubMed
    24. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53. PMID: 25626406.
      View in: PubMed
    25. Paniz-Mondolfi A, Singh R, Jour G, Mahmoodi M, Diwan AH, Barkoh BA, Cason R, Huttenbach Y, Benaim G, Galbincea J, Luthra R. Cutaneous carcinosarcoma and the EMT: to transition, or not to transition? That is the question. Virchows Arch. 2015 Mar; 466(3):359-60. PMID: 25619916.
      View in: PubMed
    26. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54. PMID: 25573287.
      View in: PubMed
    27. Mehrotra M, Luthra R, Ravandi F, Sargent RL, Barkoh BA, Abraham R, Mishra BM, Medeiros LJ, Patel KP. Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. Leuk Lymphoma. 2014 Nov; 55(11):2538-48. PMID: 24446873.
      View in: PubMed
    28. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      View in: PubMed
    29. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra R. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014 Nov 11; 111(10):2014-23. PMID: 25314059.
      View in: PubMed
    30. Vilar E, Mork ME, Cuddy A, Borras E, Bannon SA, Taggart MW, Ying J, Broaddus RR, Luthra R, Rodriguez-Bigas MA, Lynch PM, You YQ. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014 Oct-Dec; 207(10-12):495-502. PMID: 25432668.
      View in: PubMed
    31. Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014; 7:74. PMID: 25281355.
      View in: PubMed
    32. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-15. PMID: 25148578.
      View in: PubMed
    33. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8. PMID: 24990142; PMCID: PMC4431614.
    34. Paniz-Mondolfi A, Singh R, Jour G, Mahmoodi M, Diwan AH, Barkoh BA, Cason R, Huttenbach Y, Benaim G, Galbincea J, Luthra R. Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch. 2014 Sep; 465(3):339-50. PMID: 25031014.
      View in: PubMed
    35. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-14. PMID: 25009008.
      View in: PubMed
    36. Mehrotra M, Medeiros LJ, Luthra R, Sargent RL, Yao H, Barkoh BA, Singh R, Patel KP. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Hum Pathol. 2014 Oct; 45(10):1995-2005. PMID: 25128227.
      View in: PubMed
    37. Batte BA, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, Luthra R, Fellman BM, Lu KH, Broaddus RR. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. Gynecol Oncol. 2014 Aug; 134(2):319-25. PMID: 24933100; PMCID: PMC4125501.
    38. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014 Oct; 28(10):2090-2. PMID: 24854988.
      View in: PubMed
    39. Bruegl AS, Djordjevic B, Batte B, Daniels M, Fellman B, Urbauer D, Luthra R, Sun C, Lu KH, Broaddus RR. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97. PMID: 24771847.
      View in: PubMed
    40. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. PMID: 24737502.
      View in: PubMed
    41. Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014 Apr; 141(4):559-72. PMID: 24619758.
      View in: PubMed
    42. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51. PMID: 24627528; PMCID: PMC4067498.
    43. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7. PMID: 24779033; PMCID: PMC4196860.
    44. Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504. PMID: 24446311; PMCID: PMC4207363.
    45. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9. PMID: 24138309.
      View in: PubMed
    46. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. PMID: 24487412; PMCID: PMC4091714.
    47. Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol. 2014 Feb; 45(2):421-6. PMID: 24439229.
      View in: PubMed
    48. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717; PMCID: PMC4409143.
    49. Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63. PMID: 23888949.
      View in: PubMed
    50. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. PMID: 24332214.
      View in: PubMed
    51. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 1; 120(3):373-80. PMID: 24151050.
      View in: PubMed
    52. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73. PMID: 24142997.
      View in: PubMed
    53. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44. PMID: 24004182.
      View in: PubMed
    54. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809; PMCID: PMC4158732.
    55. Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61. PMID: 23940084.
      View in: PubMed
    56. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6. PMID: 24068492.
      View in: PubMed
    57. Paniz Mondolfi AE, Jour G, Johnson M, Reidy J, Cason RC, Barkoh BA, Benaim G, Singh R, Luthra R. Primary cutaneous carcinosarcoma: insights into its clonal origin and mutational pattern expression analysis through next-generation sequencing. Hum Pathol. 2013 Dec; 44(12):2853-60. PMID: 24071013.
      View in: PubMed
    58. Jaso JM, Yin CC, Lu VW, Zhao M, Abruzzo LV, You MJ, Yang Y, Luthra R, Medeiros LJ, Lu G. B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol. 2014 Mar; 27(3):382-9. PMID: 24030742.
      View in: PubMed
    59. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852; PMCID: PMC3849405.
    60. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb; 27(2):314-27. PMID: 23907151.
      View in: PubMed
    61. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920. PMID: 23896412; PMCID: PMC3798995.
    62. Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Apr; 55(4):876-83. PMID: 23772636.
      View in: PubMed
    63. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561.
      View in: PubMed
    64. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8. PMID: 23812943.
      View in: PubMed
    65. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013 Sep; 15(5):607-22. PMID: 23810757.
      View in: PubMed
    66. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      View in: PubMed
    67. Lee N, Luthra R, Lopez-Terrada D, Wang WL, Lazar AJ. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature. J Cutan Pathol. 2013 Aug; 40(8):730-3. PMID: 23672746.
      View in: PubMed
    68. Djordjevic B, Barkoh BA, Luthra R, Broaddus RR. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013 Oct; 26(10):1401-12. PMID: 23599155.
      View in: PubMed
    69. Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers. 2013 May; 17(5):429-37. PMID: 23537216; PMCID: PMC4696442.
    70. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-66. PMID: 23530930; PMCID: PMC4068703.
    71. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829.
      View in: PubMed
    72. Yin CC, Luthra R. Molecular detection of t(11;14)(q13;q32) in mantle cell lymphoma. Methods Mol Biol. 2013; 999:211-6. PMID: 23666700.
      View in: PubMed
    73. Yin CC, Luthra R. Detection of t(2;5)(p23;q35) in anaplastic large-cell lymphoma by long-range nested polymerase chain reaction assay. Methods Mol Biol. 2013; 999:217-22. PMID: 23666701.
      View in: PubMed
    74. Yin CC, Luthra R. Molecular detection of t(14;18)(q32;q21) in follicular lymphoma. Methods Mol Biol. 2013; 999:203-9. PMID: 23666699.
      View in: PubMed
    75. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013 Mar; 15(2):220-6. PMID: 23273605.
      View in: PubMed
    76. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156.
      View in: PubMed
    77. Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013 Jul; 54(7):1552. PMID: 23121011.
      View in: PubMed
    78. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9. PMID: 23115106.
      View in: PubMed
    79. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 1; 73(1):276-84. PMID: 23066039; PMCID: PMC3537862.
    80. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
      View in: PubMed
    81. Zuo Z, Medeiros LJ, Chen Z, Liu D, Bueso-Ramos CE, Luthra R, Wang SA. Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. PLoS One. 2012; 7(7):e41485. PMID: 22844482; PMCID: PMC3402404.
    82. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44. PMID: 22691121; PMCID: PMC3925981.
    83. Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012 Jul; 138(1):153-6. PMID: 22706871.
      View in: PubMed
    84. Warren M, Luthra R, Yin CC, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Zuo Z. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12. PMID: 22684224.
      View in: PubMed
    85. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. PMID: 22675430; PMCID: PMC3364990.
    86. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45. PMID: 22642896.
      View in: PubMed
    87. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 1; 118(23):5819-22. PMID: 22605576; PMCID: PMC4184417.
    88. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9. PMID: 22569880.
      View in: PubMed
    89. Deqin M, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra R. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med. 2012 May; 136(5):510-6. PMID: 22540299; PMCID: PMC3807134.
    90. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5. PMID: 22532519.
      View in: PubMed
    91. Al-Zaid T, Ditelberg JS, Prieto VG, Lev D, Luthra R, Davies MA, Diwan AH, Wang WL, Lazar AJ. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol. 2012 May; 39(5):493-9. PMID: 22486434.
      View in: PubMed
    92. Bains A, Lu G, Yao H, Luthra R, Medeiros LJ, Sargent RL. Molecular and clinicopathologic characterization of AML with isolated trisomy 4. Am J Clin Pathol. 2012 Mar; 137(3):387-94. PMID: 22338050.
      View in: PubMed
    93. Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012 May; 25(5):699-708. PMID: 22301702; PMCID: PMC3341518.
    94. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473; PMCID: PMC3295566.
    95. Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PLoS One. 2011; 6(12):e28277. PMID: 22194822.
      View in: PubMed
    96. Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila). 2012 Feb; 5(2):320-7. PMID: 22086678.
      View in: PubMed
    97. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73. PMID: 22020636; PMCID: PMC4060157.
    98. Ellezam B, Theeler BJ, Luthra R, Adesina AM, Aldape KD, Gilbert MR. Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor. Acta Neuropathol. 2012 Feb; 123(2):285-7. PMID: 21997360.
      View in: PubMed
    99. Bartley AN, Yao H, Barkoh BA, Ivan C, Mishra BM, Rashid A, Calin GA, Luthra R, Hamilton SR. Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res. 2011 Dec 1; 17(23):7283-93. PMID: 21948089; PMCID: PMC3544185.
    100. Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ, Luthra R. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. J Mol Diagn. 2011 Nov; 13(6):678-86. PMID: 21889610; PMCID: PMC3194054.
    101. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92. PMID: 21867666; PMCID: PMC4102408.
    102. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 6; 118(14):3818-23. PMID: 21821712.
      View in: PubMed
    103. Barakat FH, Luthra R, Yin CC, Barkoh BA, Hai S, Jamil W, Bhakta YI, Chen S, Medeiros LJ, Zuo Z. Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study. Arch Pathol Lab Med. 2011 Aug; 135(8):994-1000. PMID: 21809990.
      View in: PubMed
    104. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508; PMCID: PMC3146490.
    105. Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S17-24. PMID: 22035742; PMCID: PMC4845643.
    106. Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. Am J Clin Pathol. 2011 May; 135(5):686-96. PMID: 21502423.
      View in: PubMed
    107. Gurevich I, Luthra R, Konoplev SN, Yin CC, Medeiros LJ, Lin P. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings. Am J Clin Pathol. 2011 Mar; 135(3):398-403. PMID: 21350094.
      View in: PubMed
    108. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65. PMID: 21216929; PMCID: PMC3072168.
    109. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011 Jan; 135(1):35-45. PMID: 21173122.
      View in: PubMed
    110. Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011 Jan; 135(1):62-9. PMID: 21173125.
      View in: PubMed
    111. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 2; 116(23):5074-5. PMID: 21127188.
      View in: PubMed
    112. Schweighofer CD, Huh YO, Luthra R, Sargent RL, Ketterling RP, Knudson RA, Barron LL, Medeiros LJ, Keating MJ, Abruzzo LV. The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. Int J Cancer. 2011 Jun 1; 128(11):2759-64. PMID: 20715110.
      View in: PubMed
    113. Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R, Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10. PMID: 20557306; PMCID: PMC3364021.
    114. Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol. 2010 Nov; 23(11):1524-34. PMID: 20729815.
      View in: PubMed
    115. Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol. 2010 Nov; 23(11):1518-23. PMID: 20657554; PMCID: PMC2966512.
    116. Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010 Jul 29; 29(30):4362-8. PMID: 20498629.
      View in: PubMed
    117. Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol. 2010 May; 133(5):686-93. PMID: 20395514.
      View in: PubMed
    118. Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, Hamilton SR. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn. 2010 Jul; 12(4):433-40. PMID: 20413677.
      View in: PubMed
    119. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. PMID: 20212254; PMCID: PMC2930809.
    120. Lin P, Luthra R, Nussenzveig RH, Medeiros LJ. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome. Hum Pathol. 2010 May; 41(5):758-62. PMID: 20153505.
      View in: PubMed
    121. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010 Mar 11; 115(10):1985-92. PMID: 20040759; PMCID: PMC2942006.
    122. Luthra R, Zuo Z. COLD-PCR finds hot application in mutation analysis. Clin Chem. 2009 Dec; 55(12):2077-8. PMID: 19833831.
      View in: PubMed
    123. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24. PMID: 19826111.
      View in: PubMed
    124. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep 10; 114(11):2232-5. PMID: 19531657; PMCID: PMC4828071.
    125. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ, Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009 Aug; 22(8):1023-31. PMID: 19430420.
      View in: PubMed
    126. Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol. 2009 May; 131(5):647-55. PMID: 19369623.
      View in: PubMed
    127. Yin CC, Lin KI, Ketterling RP, Knudson RA, Medeiros LJ, Barron LL, Huh YO, Luthra R, Keating MJ, Abruzzo LV. Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. Am J Clin Pathol. 2009 May; 131(5):663-70. PMID: 19369625.
      View in: PubMed
    128. Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 1; 115(7):1576-85. PMID: 19156915.
      View in: PubMed
    129. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009 May; 174(5):1940-8. PMID: 19342367; PMCID: PMC2671281.
    130. Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 2009 Mar 15; 69(6):2550-8. PMID: 19244133.
      View in: PubMed
    131. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov; 33(11):1481-4. PMID: 19193436; PMCID: PMC4184059.
    132. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 1; 15(1):368-73. PMID: 19118067; PMCID: PMC4822510.
    133. Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, Wierda WG, Keating MJ, Luthra R. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn. 2009 Jan; 11(1):25-34. PMID: 19074592; PMCID: PMC2607562.
    134. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9. PMID: 19013640; PMCID: PMC4422052.
    135. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71. PMID: 19001318.
      View in: PubMed
    136. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2. PMID: 18809762.
      View in: PubMed
    137. Johnson MR, Verstovsek S, Jorgensen JL, Manshouri T, Luthra R, Jones DM, Bueso-Ramos CE, Medeiros LJ, Huh YO. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009 Jan; 22(1):50-7. PMID: 19116630.
      View in: PubMed
    138. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008 Nov 6; 27(52):6667-78. PMID: 18663355.
      View in: PubMed
    139. Lin P, Chen L, Luthra R, Konoplev SN, Wang X, Medeiros LJ. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol. 2008 Aug; 21(8):1029-36. PMID: 18536654.
      View in: PubMed
    140. Vega F, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes. Br J Haematol. 2008 Jun; 142(2):216-26. PMID: 18492102.
      View in: PubMed
    141. Huh YO, Lin KI, Vega F, Schlette E, Yin CC, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol. 2008 Jul; 142(1):36-44. PMID: 18477041.
      View in: PubMed
    142. Guo M, Gong Y, Deavers M, Silva EG, Jan YJ, Cogdell DE, Luthra R, Lin E, Lai HC, Zhang W, Sneige N. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008 Jan; 46(1):274-80. PMID: 17977987; PMCID: PMC2224284.
    143. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20; 25(33):5158-64. PMID: 17925543.
      View in: PubMed
    144. Abruzzo LV, Barron LL, Anderson K, Newman RJ, Wierda WG, O'brien S, Ferrajoli A, Luthra M, Talwalkar S, Luthra R, Jones D, Keating MJ, Coombes KR. Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. J Mol Diagn. 2007 Sep; 9(4):546-55. PMID: 17690214; PMCID: PMC1975107.
    145. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5. PMID: 17548685.
      View in: PubMed
    146. Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol. 2007 Apr; 34(2 Suppl 1):S2-6. PMID: 17449347.
      View in: PubMed
    147. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007 Feb 20; 25(6):698-707. PMID: 17308274.
      View in: PubMed
    148. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 1; 13(3):912-9. PMID: 17289885.
      View in: PubMed
    149. Izzo JG, Luthra R, Sims-Mourtada J, Chao KS, Lee JH, Wu TT, Correa AM, Luthra M, Aggarwal B, Hung MC, Ajani JA. Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S3-6. PMID: 19360144.
      View in: PubMed
    150. Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R, Zhang W. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol. 2007 Feb; 20(2):256-66. PMID: 17192787.
      View in: PubMed
    151. Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5. PMID: 17178277.
      View in: PubMed
    152. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006 Nov 1; 12(21):6565-72. PMID: 17085672.
      View in: PubMed
    153. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006 Nov; 5(11):2844-50. PMID: 17121931.
      View in: PubMed
    154. Yin CC, Medeiros LJ, Cromwell CC, Mehta AP, Lin P, Luthra R, Abruzzo LV. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. Mod Pathol. 2007 Jan; 20(1):1-7. PMID: 17057651.
      View in: PubMed
    155. Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006 Oct; 126(4):530-3. PMID: 16938665.
      View in: PubMed
    156. Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 2006 Nov; 19(11):1414-20. PMID: 16941012.
      View in: PubMed
    157. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73. PMID: 16855631.
      View in: PubMed
    158. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54. PMID: 16401681.
      View in: PubMed
    159. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, White KG, Luthra R, Lu KH. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006 Jan 1; 106(1):87-94. PMID: 16323174.
      View in: PubMed
    160. Luthra R, Medeiros LJ. TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Methods Mol Biol. 2006; 335:135-45. PMID: 16785625.
      View in: PubMed
    161. Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):178-82. PMID: 16445630.
      View in: PubMed
    162. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006 Jan 10; 24(2):259-67. PMID: 16344314.
      View in: PubMed
    163. Chen W, Jones D, Medeiros LJ, Luthra R, Lin P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol. 2005 Sep; 130(5):726-8. PMID: 16115128.
      View in: PubMed
    164. Yin CC, Glassman AB, Lin P, Valbuena JR, Jones D, Luthra R, Medeiros LJ. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol. 2005 Jun; 123(6):840-8. PMID: 15899774.
      View in: PubMed
    165. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 1; 11(9):3425-32. PMID: 15867244.
      View in: PubMed
    166. Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep. 2004 Dec; 12(6):1217-9. PMID: 15547740.
      View in: PubMed
    167. Bowman A, Jones D, Medeiros LJ, Luthra R. Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples. J Mol Diagn. 2004 Nov; 6(4):396-400. PMID: 15507680.
      View in: PubMed
    168. Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol. 2004 Sep; 122(3):348-58. PMID: 15362364.
      View in: PubMed
    169. Jones D, Ibrahim S, Patel K, Luthra R, Duvic M, Medeiros LJ. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin Cancer Res. 2004 Aug 15; 10(16):5587-94. PMID: 15328201.
      View in: PubMed
    170. Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol. 2004 Aug; 17(8):981-9. PMID: 15143336.
      View in: PubMed
    171. Luthra R, Medeiros LJ. Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens. J Mol Diagn. 2004 Aug; 6(3):236-42. PMID: 15269301; PMCID: PMC1867643.
    172. Mundhada S, Luthra R, Cano P. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). BMC Cancer. 2004 Jun 17; 4:25. PMID: 15202948; PMCID: PMC441382.
    173. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 1; 104(7):1979-88. PMID: 15198956.
      View in: PubMed
    174. Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res. 2004 Jun; 28(6):547-50. PMID: 15120929.
      View in: PubMed
    175. McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004 Jun; 28(6):712-8. PMID: 15166663.
      View in: PubMed
    176. Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004 May; 35(5):552-9. PMID: 15138928.
      View in: PubMed
    177. Luthra R, Sanchez-Vega B, Medeiros LJ. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol. 2004 Jan; 17(1):96-103. PMID: 14657955.
      View in: PubMed
    178. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004 Jan; 17(1):75-80. PMID: 14631366.
      View in: PubMed
    179. Cao SN, Chang KH, Luthra R, Liu J. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. Mod Pathol. 2003 Oct; 16(10):1048-52. PMID: 14559989.
      View in: PubMed
    180. Han XY, Pham AS, Tarrand JJ, Sood PK, Luthra R. Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol. 2002 Nov; 118(5):796-801. PMID: 12428802.
      View in: PubMed
    181. Vega F, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002 Nov 1; 100(9):3369-73. PMID: 12384439.
      View in: PubMed
    182. Thomázy VA, Luthra R, Uthman MO, Davies PJ, Medeiros LJ. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas. J Mol Diagn. 2002 Nov; 4(4):201-8. PMID: 12411587; PMCID: PMC1907355.
    183. Sanchez-Vega B, Vega F, Medeiros LJ, Lee MS, Luthra R. Quantification of bcl-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. J Mol Diagn. 2002 Nov; 4(4):223-9. PMID: 12411590.
      View in: PubMed
    184. Kabbani W, Houlihan PS, Luthra R, Hamilton SR, Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol. 2002 Jun; 15(6):599-605. PMID: 12065772.
      View in: PubMed
    185. Medeiros LJ, Hai S, Thomazy VA, Estalilla OC, Romaguera J, Luthra R. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas. Mod Pathol. 2002 May; 15(5):556-64. PMID: 12011261.
      View in: PubMed
    186. Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, Keating MJ, Jones D. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002 May; 26(5):630-6. PMID: 11979093.
      View in: PubMed
    187. Sanchez-Vega B, Vega F, Hai S, Medeiros LJ, Luthra R. Real-Time t(14;18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis: a novel and rapid approach that allows accurate quantitation and size determination of bcl-2/JH fusion sequences. Mod Pathol. 2002 Apr; 15(4):448-53. PMID: 11950920.
      View in: PubMed
    188. Vega F, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol. 2001 Sep; 116(3):410-9. PMID: 11554170.
      View in: PubMed
    189. Vega F, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Luthra R. A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol. 2001 Jul; 116(1):17-24. PMID: 11447747.
      View in: PubMed
    190. Bruckner JV, Kyle GM, Luthra R, Acosta D, Mehta SM, Sethuraman S, Muralidhara S. Acute, short-term, and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol Sci. 2001 Apr; 60(2):363-72. PMID: 11248149.
      View in: PubMed
    191. Lu D, Duvic M, Medeiros LJ, Luthra R, Dorfman DM, Jones D. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol. 2001 Mar; 115(3):413-21. PMID: 11242798.
      View in: PubMed
    192. Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I, Luthra R, Lynch PM, Amos CI. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res. 2001 Feb 15; 61(4):1269-71. PMID: 11245417.
      View in: PubMed
    193. Katz RL, Caraway NP, Gu J, Jiang F, Pasco-Miller LA, Glassman AB, Luthra R, Hayes KJ, Romaguera JE, Cabanillas FF, Medeiros LJ. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol. 2000 Aug; 114(2):248-57. PMID: 10941340.
      View in: PubMed
    194. Estalilla OC, Medeiros LJ, Manning JT, Luthra R. 5'-->3' exonuclease-based real-time PCR assays for detecting the t(14;18)(q32;21): a survey of 162 malignant lymphomas and reactive specimens. Mod Pathol. 2000 Jun; 13(6):661-6. PMID: 10874671.
      View in: PubMed
    195. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7. PMID: 10741751.
      View in: PubMed
    196. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res. 2000 Jan 15; 60(2):249-52. PMID: 10667569.
      View in: PubMed
    197. Luthra R, Sarris AH, Hai S, Paladugu AV, Romaguera JE, Cabanillas FF, Medeiros LJ. Real-time 5'-->3' exonuclease-based PCR assay for detection of the t(11;14)(q13;q32). Am J Clin Pathol. 1999 Oct; 112(4):524-30. PMID: 10510675.
      View in: PubMed
    198. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95. PMID: 10419446.
      View in: PubMed
    199. Frazier ML, Sinicrope FA, Amos CI, Cleary KR, Lynch PM, Levin B, Luthra R. Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. Oncol Rep. 1999 May-Jun; 6(3):497-505. PMID: 10203581.
      View in: PubMed
    200. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999 Feb 4; 18(5):1185-96. PMID: 10022124.
      View in: PubMed
    201. Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5' exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol. 1998 Jul; 153(1):63-8. PMID: 9665466; PMCID: PMC1852934.
    202. Sarris AH, Luthra R, Cabanillas F, Morris SW, Pugh WC. Genomic DNA amplification and the detection of t(2;5)(p23;q35) in lymphoid neoplasms. Leuk Lymphoma. 1998 May; 29(5-6):507-14. PMID: 9643564.
      View in: PubMed
    203. Luthra R, Pugh WC, Waasdorp M, Morris W, Cabanillas F, Chan PK, Sarris AH. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products. Hematopathol Mol Hematol. 1998; 11(3-4):173-83. PMID: 9844824.
      View in: PubMed
    204. Luthra R, McBride JA, Hai S, Cabanillas F, Pugh WC. The application of fluorescence-based PCR and PCR-SSCP to monitor the clonal relationship of cells bearing the t(14;18)(q32;q21) in sequential biopsy specimens from patients with follicle center cell lymphoma. Diagn Mol Pathol. 1997 Apr; 6(2):71-7. PMID: 9098644.
      View in: PubMed
    205. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol. 1997; 8 Suppl 2:59-63. PMID: 9209643.
      View in: PubMed
    206. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood. 1996 Sep 1; 88(5):1771-9. PMID: 8781434.
      View in: PubMed
    207. McBride JA, Rodriguez J, Luthra R, Ordóñez NG, Cabanillas F, Pugh WC. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol. 1996 Feb; 20(2):193-201. PMID: 8554109.
      View in: PubMed
    208. Luthra R, Hai S, Pugh WC. Polymerase chain reaction detection of the t(11;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma. Diagn Mol Pathol. 1995 Mar; 4(1):4-7. PMID: 7735555.
      View in: PubMed
    209. Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB, McLaughlin P, Rodriguez MA, Swan F, Cabanillas F. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994 Nov; 5(9):847-9. PMID: 7848887.
      View in: PubMed
    210. Romaguera JE, Pugh W, Luthra R, Goodacre A, Cabanillas F. The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma. Ann Oncol. 1993 Jan; 4(1):51-4. PMID: 8435363.
      View in: PubMed
    211. Heindel JJ, Berkowitz AS, Kyle G, Luthra R, Bruckner JV. Assessment in rats of the gonadotoxic and hepatorenal toxic potential of dibromochloropropane (DBCP) in drinking water. Fundam Appl Toxicol. 1989 Nov; 13(4):804-15. PMID: 2620797.
      View in: PubMed
    212. Bruckner JV, MacKenzie WF, Muralidhara S, Luthra R, Kyle GM, Acosta D. Oral toxicity of carbon tetrachloride: acute, subacute, and subchronic studies in rats. Fundam Appl Toxicol. 1986 Jan; 6(1):16-34. PMID: 3710021.
      View in: PubMed
    213. Luthra R, Kyle GM, Mehta PS, Bruckner JV. Effects of carbon tetrachloride and 1,1-dichloroethylene on rat hepatic microsomal calcium- and/or magnesium-stimulated ATPase. Biochem Pharmacol. 1984 Oct 15; 33(20):3295-8. PMID: 6148949.
      View in: PubMed
    214. Kyle GM, Luthra R, Bruckner JV, MacKenzie WF, Acosta D. Assessment of functional, morphological, and enzymatic tests for acute nephrotoxicity induced by mercuric chloride. J Toxicol Environ Health. 1983 Jul; 12(1):99-117. PMID: 6226807.
      View in: PubMed
    215. Luthra R, Olson MS. The effects of chlorotetracycline on calcium movements in isolated rat liver mitochondria. Arch Biochem Biophys. 1978 Dec; 191(2):494-502. PMID: 742885.
      View in: PubMed
    216. Luthra R, Olson MS. The inhibition of calcium uptake and release by rat liver mitochondria by ruthenium red. FEBS Lett. 1977 Sep 1; 81(1):142-6. PMID: 902768.
      View in: PubMed
    217. Luthra R, Olson MS. Studies of mitochondrial calcium movements using chlorotetracycline. Biochim Biophys Acta. 1976 Sep 13; 440(3):744-58. PMID: 822874.
      View in: PubMed
    218. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.
    219. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    220. Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.
    221. Investigation of biochemical indices of hepatotoxicity. Pharmacologist. 23.
    222. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology.
    223. Identification of factors affecting the success of next-generation sequencing testing in solid tumors. American Journal of Clinical Pathology. 145:222-237.
    224. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis. Human Pathology. 52:61-67.
    225. Mutation analysis in cancer. 261-279.
    226. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    227. Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]. Oncotarget. 6:24581.
    228. Influence of time of exposure to carbon tetrachloride on toxic liver injury. Annual Review of Chronopharmacology. VOL. 1:373-376.
    229. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics. 1-12.
    230. Epstein-barr virus and cytomegalovirus viral load monitoring by quantitative real-time polymerase chain reaction. 171-186.
    231. Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies. Cancers. 7:1699-1715.
    232. Primary intracranial soft tissue sarcomas in children, adolescents, and young adults. Journal of Neuro-Oncology. 127:155-163.
    233. Oral toxicity of carbon tetrachioride. Toxicological Sciences. 6:16-34.
    234. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American Journal of Clinical Pathology. 145:418-427.
    235. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. European Journal of Haematology.
    236. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clinical Cancer Research. 21:2644-2651.
    237. Journal of Molecular Diagnostics. 18:676-687.
    238. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 7:14251-14258.
    239. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.
    240. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.
    241. Molecular strategies in the diagnosis of malignant lymphoma and lymphoproliferative disorders. Cancer Bulletin. 45:29-36.
    242. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.
    243. Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers. International Journal of Gynecological Pathology. 35:8-15.
    244. Next-generation sequencing in clinical molecular diagnostics of cancer. Cancers. 7:2023-2036.
    245. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia. 16:395-403.e1.
    246. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.
    247. Pyrosequencing in cancer. 295-306.
    248. Minimal residual disease. 281-293.
    249. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.
    250. Evaluation of clinical criteria for the identification of lynch syndrome among unselected endometrial cancer patients. Obstetrical and Gynecological Survey. 69:541-542.
    251. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Molecular Cytogenetics. 8.
    252. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer.
    253. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology. 28:1225-1235.
    254. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6:12809-12821.
    255. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.
    256. Validation and implementation of next-generation sequencing technologies in a clinical molecular diagnostic laboratory. 127-136.
    257. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology. 8.
    258. Inflammation mediated metastasis. PLoS One. 10.
    259. How do we make clinical molecular testing for cancer standard of care for pathology departments?. JNCCN Journal of the National Comprehensive Cancer Network. 14:787-792.
    260. Crystal-storing histiocytosis. Histopathology. 68:482-491.
    261. Journal of Clinical Ligand Assay. 23:6-14.
    262. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.
    263. Sensitivity and specificity of tests for chemically-induced nephrotoxicity. Pharmacologist. 23.
    264. Advances in clinical next-generation sequencing. Expert Review of Molecular Diagnostics. 16:357-372.
    LUTHRA's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description